Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘transformed follicular lymphoma’

Beyond R-CHOP: New Frontiers in Lymphoma Treatment at ASH 2024

Even the cars stand out in San Diego

After writing of some trials and tribulations in solid tumours earlier this week (see review of the Janux TRACTR here), it was rather nice to return to my old stamping ground of hematologic malignancies and feel soothed by both the familiar and also incoming novel approaches for a variety of different conditions.

It is exactly twenty five years since the initial phase 1 data for STI-571 (now known as imatinib or Gleevec) were first presented in an ASH Plenary.  31 out of 31 advanced CML patients responded and Dr Brian Druker received an outstanding ovation at the end of his presentation.  It was the kind of stuff that gave you goosebumps – despite the freezing cold hangar.

This is the kind of thing hematologists and companies alike live for; it’s what gets you jumping out of bed in the morning to help make a difference to the lives of cancer patients.

At ASH this year there are some encouraging data on early stage trials coming out in several hematologic malignancies, which kept me occupied and fascinated for most of the first day of the meeting.  There’ll be another detailed write up of one of these areas tomorrow morning, while a different condition offered a raft of choices across single agent therapy and combinations alike.

Here we highlight what to watch out for – both positive and negative – on five agents with encouraging early data, which caught out attention yesterday.  They include bispecific T cell engagers and cell therapies – what’s not to like?

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

A look at 6 key developments in advanced hematologic malignancies

Stacking up the evidence

Not everything at ASCO is necessarily focused on solid tumours, there’s often some useful hints of progress on the hematologic malignancies front too.

Here we look at the building evidence for half a dozen such developments across myeloma, lymphomas, and acute leukemias.

To be clear this doesn’t mean they will all be of the good news type because sometimes early developments promise much and fizzle out over time.

This is the advantage of following compounds and technologies in new product development over time – you get to see them as they really are and not through the lens of rose tinted glasses….

BSB subscribers can read more on our latest update regarding immunotherapies not checkpoint blockade in hematologic malignancies  – you can log-in or click to access our ongoing ASCO21 coverage.

This content is restricted to subscribers

A critical review of bispecific antibodies at ASH20

We are big fans of the American Society of Hematology (ASH) annual meeting, it certainly is the global meeting for hematology! The quality of research presented is very high; it’s where you see groundbreaking and practice changing hematology data, sometimes from unexpected sources.

Last year brought us long lines, crowded escalators, and jam packed halls, especially for the niche sessions.  It’s hard to imagine any of these in pandemic these days, especially if someone were to start suddenly coughing and sneezing in the seat behind…

A bit of nostalgia from ASH19: Up close and personal

Will we all be together again for #ASH21? According to virology experts, we’ll need 70% of people (around the world, not just in one country!) to have had a COVID-19 vaccine before we can lower our masks and do away with social distancing.

Even if 70% of health care professionals are vaccinated, a not unrealistic figure if you look at the flu vaccine uptake, going to an in-person meeting means you still have to navigate the cumulative risk associated with airports, flights, hotels, ground transportation, plus eating out in an urban environment where the very visible inequality that exists in America means it is highly unlikely everyone you may come into contact with, directly or indirectly, will be vaccinated.

There’s also the uncertainty of how durable any vaccination is, raising the prospect that any COVID-19 vaccination is unlikely to be “once and done” – will we all need boosts six months later? The logistics for all of this are just mind blowing.

Despite the exhortations from ASH leadership that they look forward to seeing us in Georgia next year at #ASH21 and we should all plan to be there, as things stand we don’t recommend booking your flights to Atlanta and #ASH21 just yet.

BSB expects 2021 to be another year of virtual meetings!

Meanwhile, on with the business of exploring the emerging data from ASH 20.

In this latest post, we are highlighting a few of the presentations that caught our attention on the various bispecific antibodies and T cell engagers in advanced lymphomas and multiple myeloma…

To learn more from our oncology analysis and get a heads up on the latest insights and commentary pertaining to the ASH meeting — including our daily highlights coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

ASH17 Preview of emerging therapies for Aggressive Lymphomas

And we’re off on the infamous ASH DASH…

Atlanta Centennial Olympic Park

The annual data drop for the American Society of Hematology (ASH) meeting in Atlanta, Georgia is finally here.

Each year we write a series of in-depth previews ahead of the event exploring different aspects of hematologic malignancies in terms of what’s important, what to watch out for, and also key abstracts that may (or may not) have an impact.

This year we kick off the first of our series with a look at aggressive lymphomas and novel therapies in development including CAR T cell therapies, antibodies, ADCs and targeted therapies. There are some surprsies (of course) and also some potentially interesting relationships and consequences to consider.

To learn more insights on this intriguing topic, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

error: Content is protected !!